IDEAYA Biosciences, Inc. (IDYA) 10-Year Financial Performance & Capital Metrics

IDYA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutIDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Show more

Revenue $7M -70.1%
EBITDA -$323M -147.8%
Net Income -$274M -143.0%
EPS (Diluted) -3.36 -71.4%
Gross Margin 45.23% -45.4%
EBITDA Margin -4616.3% -727.7%
Operating Margin -4671.07% -712.6%
Net Margin -3921.1% -711.7%
ROE -32.67% -40.4%
ROIC -33.57% -25.1%
Debt/Equity 0.02 +291.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 89 (top 11%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Shares diluted 42.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-36.96%

TTM5376.27%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM9.76%

EPS CAGR

10Y-

5Y-

3Y-

TTM20.17%

ROCE

10Y Avg-41.21%

5Y Avg-24.04%

3Y Avg-28%

Latest-38.46%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	19.54M	27.94M	50.93M	23.39M	7M
Revenue Growth %	-	-	-	-	0.43%	0.82%	-0.54%	-0.7%
Cost of Goods Sold+	391K	886K	1.25M	1.38M	1.73M	2.1M	4.01M	3.83M
COGS % of Revenue	-	-	-	0.07%	0.06%	0.04%	0.17%	0.55%
Gross Profit+	-391K	-886K	-1.25M	18.16M	26.22M	48.83M	19.38M	3.17M
Gross Margin %	-	-	-	0.93%	0.94%	0.96%	0.83%	0.45%
Gross Profit Growth %	-	-1.27%	-0.41%	15.58%	0.44%	0.86%	-0.6%	-0.84%
Operating Expenses+	14.05M	35.53M	43.03M	53.5M	76.48M	111.33M	153.81M	330.14M
OpEx % of Revenue	-	-	-	2.74%	2.74%	2.19%	6.58%	47.16%
Selling, General & Admin	1.66M	3.78M	8.71M	13.8M	18.33M	21.8M	24.3M	35.47M
SG&A % of Revenue	-	-	-	0.71%	0.66%	0.43%	1.04%	5.07%
Research & Development	12.38M	31.75M	34.32M	39.7M	58.16M	89.54M	129.51M	294.67M
R&D % of Revenue	-	-	-	2.03%	2.08%	1.76%	5.54%	42.1%
Other Operating Expenses	0	0	0	0	0	0	0	0
Operating Income+	-14.44M	-36.42M	-44.27M	-35.34M	-50.27M	-62.5M	-134.43M	-326.98M
Operating Margin %	-	-	-	-1.81%	-1.8%	-1.23%	-5.75%	-46.71%
Operating Income Growth %	-	-1.52%	-0.22%	0.2%	-0.42%	-0.24%	-1.15%	-1.43%
EBITDA+	-14.05M	-35.53M	-43.03M	-33.96M	-48.54M	-60.4M	-130.42M	-323.14M
EBITDA Margin %	-	-	-	-1.74%	-1.74%	-1.19%	-5.58%	-46.16%
EBITDA Growth %	-	-1.53%	-0.21%	0.21%	-0.43%	-0.24%	-1.16%	-1.48%
D&A (Non-Cash Add-back)	391K	886K	1.25M	1.38M	1.73M	2.1M	4.01M	3.83M
EBIT	-11.86M	-34.35M	-41.98M	-34.49M	-49.76M	-58.66M	-112.96M	-274.48M
Net Interest Income+	150K	1.99M	2.29M	849K	506K	3.85M	21.47M	52.5M
Interest Income	150K	1.99M	2.29M	849K	506K	3.85M	21.47M	52.5M
Interest Expense	0	0	0	0	0	0	0	0
Other Income/Expense	2.58M	2.07M	2.3M	849K	506K	3.85M	21.47M	52.5M
Pretax Income+	-11.86M	-34.35M	-41.98M	-34.49M	-49.76M	-58.66M	-112.96M	-274.48M
Pretax Margin %	-	-	-	-1.77%	-1.78%	-1.15%	-4.83%	-39.21%
Income Tax+	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-11.86M	-34.35M	-41.98M	-34.49M	-49.76M	-58.66M	-112.96M	-274.48M
Net Margin %	-	-	-	-1.77%	-1.78%	-1.15%	-4.83%	-39.21%
Net Income Growth %	-	-1.9%	-0.22%	0.18%	-0.44%	-0.18%	-0.93%	-1.43%
Net Income (Continuing)	-11.86M	-34.35M	-41.98M	-34.49M	-49.76M	-58.66M	-112.96M	-274.48M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.83	-2.41	-1.90	-1.31	-1.41	-1.42	-1.96	-3.36
EPS Growth %	-	-1.9%	0.21%	0.31%	-0.08%	-0.01%	-0.38%	-0.71%
EPS (Basic)	-0.83	-2.41	-1.90	-1.31	-1.41	-1.42	-1.96	-3.36
Diluted Shares Outstanding	14.24M	14.24M	20.23M	24.72M	35.25M	41.44M	57.52M	81.68M
Basic Shares Outstanding	14.24M	14.24M	20.23M	24.72M	35.25M	41.44M	57.52M	81.68M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	13.58M	90.67M	101.65M	288.61M	251M	370.45M	532.63M	689.71M
Cash & Short-Term Investments	13.16M	89.96M	98.96M	283.58M	246.77M	364.83M	525.11M	676.32M
Cash Only	5.96M	20.5M	34.07M	72.04M	92.05M	68.63M	157.02M	84.38M
Short-Term Investments	7.2M	69.46M	64.89M	211.55M	154.72M	296.2M	368.1M	591.94M
Accounts Receivable	0	0	0	1.88M	1.1M	211K	18K	3K
Days Sales Outstanding	-	-	-	35.07	14.41	1.51	0.28	0.16
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	5.41M	7.5M	13.39M
Total Non-Current Assets+	3.9M	5.87M	11.35M	9.66M	130.35M	17.52M	116.68M	434.38M
Property, Plant & Equipment	3.74M	5.15M	9.7M	9.48M	8.66M	8.99M	8.41M	27.74M
Fixed Asset Turnover	-	-	-	2.06x	3.23x	5.66x	2.78x	0.25x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	71K	0	1.53M	0	121.29M	8.32M	107.49M	405.83M
Other Non-Current Assets	89K	722K	122K	188K	397K	205K	782K	805K
Total Assets+	17.48M	96.54M	113M	298.27M	381.35M	387.97M	649.32M	1.12B
Asset Turnover	-	-	-	0.07x	0.07x	0.13x	0.04x	0.01x
Asset Growth %	-	4.52%	0.17%	1.64%	0.28%	0.02%	0.67%	0.73%
Total Current Liabilities+	2.43M	5.41M	6.94M	38.64M	45.16M	31.72M	27.1M	46.07M
Accounts Payable	662K	1.42M	709K	953K	2.1M	4.28M	6.6M	15.42M
Days Payables Outstanding	617.98	583.75	207.86	251.88	444.35	743.55	600.87	1.47K
Short-Term Debt	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	297K	0	0	1000K	1000K	1000K	0	0
Other Current Liabilities	728K	413K	63K	18K	0	0	11.78M	30.35M
Current Ratio	5.58x	16.75x	14.65x	7.47x	5.56x	11.68x	19.65x	14.97x
Quick Ratio	5.58x	16.75x	14.65x	7.47x	5.56x	11.68x	19.65x	14.97x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	30.78M	140.08M	5.66M	61.35M	34.67M	6.8M	1.13M	18.87M
Long-Term Debt	3.21M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	5.63M	5.18M	3.48M	1.61M	1.13M	18.87M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	27.58M	140.08M	34K	12K	0	0	0	0
Total Liabilities	33.22M	145.49M	12.6M	100M	79.83M	38.51M	28.23M	64.94M
Total Debt+	3.21M	0	6.77M	6.72M	5.18M	3.48M	2.87M	19.17M
Net Debt	-2.75M	-20.5M	-27.3M	-65.31M	-86.86M	-65.15M	-154.15M	-65.21M
Debt / Equity	-	-	0.07x	0.03x	0.02x	0.01x	0.00x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-
Total Equity+	-15.74M	-48.95M	100.4M	198.27M	301.51M	349.45M	621.09M	1.06B
Equity Growth %	-	-2.11%	3.05%	0.97%	0.52%	0.16%	0.78%	0.71%
Book Value per Share	-1.11	-3.44	4.96	8.02	8.55	8.43	10.80	12.97
Total Shareholders' Equity	-15.74M	-48.95M	100.4M	198.27M	301.51M	349.45M	621.09M	1.06B
Common Stock	1K	0	2K	3K	4K	5K	7K	9K
Retained Earnings	-16.17M	-50.52M	-92.49M	-126.99M	-176.75M	-235.4M	-348.36M	-622.84M
Treasury Stock	-431K	0	0	0	0	0	0	0
Accumulated OCI	-1K	-31K	65K	7K	-712K	-2.87M	562K	812K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-12.22M	-27.62M	-39.31M	55.46M	-55.78M	-87.17M	-115.22M	-247.58M
Operating CF Margin %	-	-	-	2.84%	-2%	-1.71%	-4.93%	-35.37%
Operating CF Growth %	-	-1.26%	-0.42%	2.41%	-2.01%	-0.56%	-0.32%	-1.15%
Net Income	-11.86M	-34.35M	-41.98M	-34.49M	-49.76M	-58.66M	-112.96M	-274.48M
Depreciation & Amortization	391K	886K	1.25M	1.38M	1.73M	2.1M	4.01M	3.83M
Stock-Based Compensation	136K	950K	2.17M	3.61M	8.24M	11.63M	18.49M	34.75M
Deferred Taxes	-27K	-873K	0	0	0	0	0	0
Other Non-Cash Items	-2.43M	4.11M	-467K	562K	1.83M	-695K	-11.55M	-23.23M
Working Capital Changes	1.56M	1.65M	-284K	84.41M	-17.81M	-41.55M	-13.21M	11.55M
Change in Receivables	0	0	0	-1.88M	774K	892K	193K	15K
Change in Inventory	0	0	0	2.29M	3.79M	0	0	0
Change in Payables	254K	322K	-195K	225K	1.17M	1.86M	2.63M	8.28M
Cash from Investing+	-8.93M	-63.18M	2.27M	-146.24M	-69.67M	-33.4M	-158.46M	-502.56M
Capital Expenditures	-1.76M	-1.71M	-1.35M	-493K	-2.64M	-3.44M	-2.37M	-3.86M
CapEx % of Revenue	-	-	-	0.03%	0.09%	0.07%	0.1%	0.55%
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	8K	18K	-67.02M	-33.4M	0	0
Cash from Financing+	17.49M	105.38M	50.61M	128.75M	145.45M	97.17M	362.72M	677.55M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	226K	20K	289K	1.52M	2.2M	2.2M	10.77M	13.92M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-13.98M	-29.33M	-40.67M	54.97M	-58.42M	-90.62M	-117.59M	-251.44M
FCF Margin %	-	-	-	2.81%	-2.09%	-1.78%	-5.03%	-35.92%
FCF Growth %	-	-1.1%	-0.39%	2.35%	-2.06%	-0.55%	-0.3%	-1.14%
FCF per Share	-0.98	-2.06	-2.01	2.22	-1.66	-2.19	-2.04	-3.08
FCF Conversion (FCF/Net Income)	1.03x	0.80x	0.94x	-1.61x	1.12x	1.49x	1.02x	0.90x
Interest Paid	0	99K	91K	82K	71K	0	0	0
Taxes Paid	0	1K	1K	1K	4K	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-163.16%	-23.1%	-19.91%	-18.02%	-23.28%	-32.67%
Return on Invested Capital (ROIC)	-	-	-1818.36%	-25.73%	-21.69%	-18.79%	-26.84%	-33.57%
Gross Margin	-	-	-	92.93%	93.83%	95.87%	82.86%	45.23%
Net Margin	-	-	-	-176.55%	-178.1%	-115.17%	-483.05%	-3921.1%
Debt / Equity	-	-	0.07x	0.03x	0.02x	0.01x	0.00x	0.02x
FCF Conversion	1.03x	0.80x	0.94x	-1.61x	1.12x	1.49x	1.02x	0.90x
Revenue Growth	-	-	-	-	43.01%	82.28%	-54.08%	-70.07%

Revenue by Segment

	2020	2021	2022
Methionine Adenosyl Transferase2 A Program Supply	2.35M	2.41M	2.4M
Methionine Adenosyl Transferase2 A Program Supply Growth	-	2.55%	-0.46%
Werner Helicase Program Research And Development Service	27.79M	20.83M	-
Werner Helicase Program Research And Development Service Growth	-	-25.04%	-
The Option	17.23M	17.68M	-
The Option Growth	-	2.58%	-
Polymerase Theta Program Research And Development Service	25.78M	13.75M	-
Polymerase Theta Program Research And Development Service Growth	-	-46.65%	-
Methionine Adenosyl Transferase2 A Program Research And Development	16.14M	9.49M	-
Methionine Adenosyl Transferase2 A Program Research And Development Growth	-	-41.24%	-

Frequently Asked Questions

Growth & Financials

IDEAYA Biosciences, Inc. (IDYA) reported $214.8M in revenue for fiscal year 2024.

IDEAYA Biosciences, Inc. (IDYA) saw revenue decline by 70.1% over the past year.

IDEAYA Biosciences, Inc. (IDYA) reported a net loss of $160.7M for fiscal year 2024.

Dividend & Returns

IDEAYA Biosciences, Inc. (IDYA) has a return on equity (ROE) of -32.7%. Negative ROE indicates the company is unprofitable.

IDEAYA Biosciences, Inc. (IDYA) had negative free cash flow of $105.4M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

IDEAYA Biosciences, Inc. (IDYA) 10-Year Financial Performance & Capital Metrics

IDYA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $7M -70.1%
EBITDA -$323M -147.8%
Net Income -$274M -143.0%
EPS (Diluted) -3.36 -71.4%
Gross Margin 45.23% -45.4%
EBITDA Margin -4616.3% -727.7%
Operating Margin -4671.07% -712.6%
Net Margin -3921.1% -711.7%
ROE -32.67% -40.4%
ROIC -33.57% -25.1%
Debt/Equity 0.02 +291.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 89 (top 11%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Shares diluted 42.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-36.96%

TTM5376.27%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM9.76%

EPS CAGR

10Y-

5Y-

3Y-

TTM20.17%

ROCE

10Y Avg-41.21%

5Y Avg-24.04%

3Y Avg-28%

Latest-38.46%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	19.54M	27.94M	50.93M	23.39M	7M
Revenue Growth %	-	-	-	-	0.43%	0.82%	-0.54%	-0.7%
Cost of Goods Sold+	391K	886K	1.25M	1.38M	1.73M	2.1M	4.01M	3.83M
COGS % of Revenue	-	-	-	0.07%	0.06%	0.04%	0.17%	0.55%
Gross Profit+	-391K	-886K	-1.25M	18.16M	26.22M	48.83M	19.38M	3.17M
Gross Margin %	-	-	-	0.93%	0.94%	0.96%	0.83%	0.45%
Gross Profit Growth %	-	-1.27%	-0.41%	15.58%	0.44%	0.86%	-0.6%	-0.84%
Operating Expenses+	14.05M	35.53M	43.03M	53.5M	76.48M	111.33M	153.81M	330.14M
OpEx % of Revenue	-	-	-	2.74%	2.74%	2.19%	6.58%	47.16%
Selling, General & Admin	1.66M	3.78M	8.71M	13.8M	18.33M	21.8M	24.3M	35.47M
SG&A % of Revenue	-	-	-	0.71%	0.66%	0.43%	1.04%	5.07%
Research & Development	12.38M	31.75M	34.32M	39.7M	58.16M	89.54M	129.51M	294.67M
R&D % of Revenue	-	-	-	2.03%	2.08%	1.76%	5.54%	42.1%
Other Operating Expenses	0	0	0	0	0	0	0	0
Operating Income+	-14.44M	-36.42M	-44.27M	-35.34M	-50.27M	-62.5M	-134.43M	-326.98M
Operating Margin %	-	-	-	-1.81%	-1.8%	-1.23%	-5.75%	-46.71%
Operating Income Growth %	-	-1.52%	-0.22%	0.2%	-0.42%	-0.24%	-1.15%	-1.43%
EBITDA+	-14.05M	-35.53M	-43.03M	-33.96M	-48.54M	-60.4M	-130.42M	-323.14M
EBITDA Margin %	-	-	-	-1.74%	-1.74%	-1.19%	-5.58%	-46.16%
EBITDA Growth %	-	-1.53%	-0.21%	0.21%	-0.43%	-0.24%	-1.16%	-1.48%
D&A (Non-Cash Add-back)	391K	886K	1.25M	1.38M	1.73M	2.1M	4.01M	3.83M
EBIT	-11.86M	-34.35M	-41.98M	-34.49M	-49.76M	-58.66M	-112.96M	-274.48M
Net Interest Income+	150K	1.99M	2.29M	849K	506K	3.85M	21.47M	52.5M
Interest Income	150K	1.99M	2.29M	849K	506K	3.85M	21.47M	52.5M
Interest Expense	0	0	0	0	0	0	0	0
Other Income/Expense	2.58M	2.07M	2.3M	849K	506K	3.85M	21.47M	52.5M
Pretax Income+	-11.86M	-34.35M	-41.98M	-34.49M	-49.76M	-58.66M	-112.96M	-274.48M
Pretax Margin %	-	-	-	-1.77%	-1.78%	-1.15%	-4.83%	-39.21%
Income Tax+	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-11.86M	-34.35M	-41.98M	-34.49M	-49.76M	-58.66M	-112.96M	-274.48M
Net Margin %	-	-	-	-1.77%	-1.78%	-1.15%	-4.83%	-39.21%
Net Income Growth %	-	-1.9%	-0.22%	0.18%	-0.44%	-0.18%	-0.93%	-1.43%
Net Income (Continuing)	-11.86M	-34.35M	-41.98M	-34.49M	-49.76M	-58.66M	-112.96M	-274.48M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.83	-2.41	-1.90	-1.31	-1.41	-1.42	-1.96	-3.36
EPS Growth %	-	-1.9%	0.21%	0.31%	-0.08%	-0.01%	-0.38%	-0.71%
EPS (Basic)	-0.83	-2.41	-1.90	-1.31	-1.41	-1.42	-1.96	-3.36
Diluted Shares Outstanding	14.24M	14.24M	20.23M	24.72M	35.25M	41.44M	57.52M	81.68M
Basic Shares Outstanding	14.24M	14.24M	20.23M	24.72M	35.25M	41.44M	57.52M	81.68M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	13.58M	90.67M	101.65M	288.61M	251M	370.45M	532.63M	689.71M
Cash & Short-Term Investments	13.16M	89.96M	98.96M	283.58M	246.77M	364.83M	525.11M	676.32M
Cash Only	5.96M	20.5M	34.07M	72.04M	92.05M	68.63M	157.02M	84.38M
Short-Term Investments	7.2M	69.46M	64.89M	211.55M	154.72M	296.2M	368.1M	591.94M
Accounts Receivable	0	0	0	1.88M	1.1M	211K	18K	3K
Days Sales Outstanding	-	-	-	35.07	14.41	1.51	0.28	0.16
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	5.41M	7.5M	13.39M
Total Non-Current Assets+	3.9M	5.87M	11.35M	9.66M	130.35M	17.52M	116.68M	434.38M
Property, Plant & Equipment	3.74M	5.15M	9.7M	9.48M	8.66M	8.99M	8.41M	27.74M
Fixed Asset Turnover	-	-	-	2.06x	3.23x	5.66x	2.78x	0.25x
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0
Long-Term Investments	71K	0	1.53M	0	121.29M	8.32M	107.49M	405.83M
Other Non-Current Assets	89K	722K	122K	188K	397K	205K	782K	805K
Total Assets+	17.48M	96.54M	113M	298.27M	381.35M	387.97M	649.32M	1.12B
Asset Turnover	-	-	-	0.07x	0.07x	0.13x	0.04x	0.01x
Asset Growth %	-	4.52%	0.17%	1.64%	0.28%	0.02%	0.67%	0.73%
Total Current Liabilities+	2.43M	5.41M	6.94M	38.64M	45.16M	31.72M	27.1M	46.07M
Accounts Payable	662K	1.42M	709K	953K	2.1M	4.28M	6.6M	15.42M
Days Payables Outstanding	617.98	583.75	207.86	251.88	444.35	743.55	600.87	1.47K
Short-Term Debt	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	297K	0	0	1000K	1000K	1000K	0	0
Other Current Liabilities	728K	413K	63K	18K	0	0	11.78M	30.35M
Current Ratio	5.58x	16.75x	14.65x	7.47x	5.56x	11.68x	19.65x	14.97x
Quick Ratio	5.58x	16.75x	14.65x	7.47x	5.56x	11.68x	19.65x	14.97x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	30.78M	140.08M	5.66M	61.35M	34.67M	6.8M	1.13M	18.87M
Long-Term Debt	3.21M	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	5.63M	5.18M	3.48M	1.61M	1.13M	18.87M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	27.58M	140.08M	34K	12K	0	0	0	0
Total Liabilities	33.22M	145.49M	12.6M	100M	79.83M	38.51M	28.23M	64.94M
Total Debt+	3.21M	0	6.77M	6.72M	5.18M	3.48M	2.87M	19.17M
Net Debt	-2.75M	-20.5M	-27.3M	-65.31M	-86.86M	-65.15M	-154.15M	-65.21M
Debt / Equity	-	-	0.07x	0.03x	0.02x	0.01x	0.00x	0.02x
Debt / EBITDA	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-
Total Equity+	-15.74M	-48.95M	100.4M	198.27M	301.51M	349.45M	621.09M	1.06B
Equity Growth %	-	-2.11%	3.05%	0.97%	0.52%	0.16%	0.78%	0.71%
Book Value per Share	-1.11	-3.44	4.96	8.02	8.55	8.43	10.80	12.97
Total Shareholders' Equity	-15.74M	-48.95M	100.4M	198.27M	301.51M	349.45M	621.09M	1.06B
Common Stock	1K	0	2K	3K	4K	5K	7K	9K
Retained Earnings	-16.17M	-50.52M	-92.49M	-126.99M	-176.75M	-235.4M	-348.36M	-622.84M
Treasury Stock	-431K	0	0	0	0	0	0	0
Accumulated OCI	-1K	-31K	65K	7K	-712K	-2.87M	562K	812K
Minority Interest	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-12.22M	-27.62M	-39.31M	55.46M	-55.78M	-87.17M	-115.22M	-247.58M
Operating CF Margin %	-	-	-	2.84%	-2%	-1.71%	-4.93%	-35.37%
Operating CF Growth %	-	-1.26%	-0.42%	2.41%	-2.01%	-0.56%	-0.32%	-1.15%
Net Income	-11.86M	-34.35M	-41.98M	-34.49M	-49.76M	-58.66M	-112.96M	-274.48M
Depreciation & Amortization	391K	886K	1.25M	1.38M	1.73M	2.1M	4.01M	3.83M
Stock-Based Compensation	136K	950K	2.17M	3.61M	8.24M	11.63M	18.49M	34.75M
Deferred Taxes	-27K	-873K	0	0	0	0	0	0
Other Non-Cash Items	-2.43M	4.11M	-467K	562K	1.83M	-695K	-11.55M	-23.23M
Working Capital Changes	1.56M	1.65M	-284K	84.41M	-17.81M	-41.55M	-13.21M	11.55M
Change in Receivables	0	0	0	-1.88M	774K	892K	193K	15K
Change in Inventory	0	0	0	2.29M	3.79M	0	0	0
Change in Payables	254K	322K	-195K	225K	1.17M	1.86M	2.63M	8.28M
Cash from Investing+	-8.93M	-63.18M	2.27M	-146.24M	-69.67M	-33.4M	-158.46M	-502.56M
Capital Expenditures	-1.76M	-1.71M	-1.35M	-493K	-2.64M	-3.44M	-2.37M	-3.86M
CapEx % of Revenue	-	-	-	0.03%	0.09%	0.07%	0.1%	0.55%
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	0	0	8K	18K	-67.02M	-33.4M	0	0
Cash from Financing+	17.49M	105.38M	50.61M	128.75M	145.45M	97.17M	362.72M	677.55M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	226K	20K	289K	1.52M	2.2M	2.2M	10.77M	13.92M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	-13.98M	-29.33M	-40.67M	54.97M	-58.42M	-90.62M	-117.59M	-251.44M
FCF Margin %	-	-	-	2.81%	-2.09%	-1.78%	-5.03%	-35.92%
FCF Growth %	-	-1.1%	-0.39%	2.35%	-2.06%	-0.55%	-0.3%	-1.14%
FCF per Share	-0.98	-2.06	-2.01	2.22	-1.66	-2.19	-2.04	-3.08
FCF Conversion (FCF/Net Income)	1.03x	0.80x	0.94x	-1.61x	1.12x	1.49x	1.02x	0.90x
Interest Paid	0	99K	91K	82K	71K	0	0	0
Taxes Paid	0	1K	1K	1K	4K	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-163.16%	-23.1%	-19.91%	-18.02%	-23.28%	-32.67%
Return on Invested Capital (ROIC)	-	-	-1818.36%	-25.73%	-21.69%	-18.79%	-26.84%	-33.57%
Gross Margin	-	-	-	92.93%	93.83%	95.87%	82.86%	45.23%
Net Margin	-	-	-	-176.55%	-178.1%	-115.17%	-483.05%	-3921.1%
Debt / Equity	-	-	0.07x	0.03x	0.02x	0.01x	0.00x	0.02x
FCF Conversion	1.03x	0.80x	0.94x	-1.61x	1.12x	1.49x	1.02x	0.90x
Revenue Growth	-	-	-	-	43.01%	82.28%	-54.08%	-70.07%

Revenue by Segment

	2020	2021	2022
Methionine Adenosyl Transferase2 A Program Supply	2.35M	2.41M	2.4M
Methionine Adenosyl Transferase2 A Program Supply Growth	-	2.55%	-0.46%
Werner Helicase Program Research And Development Service	27.79M	20.83M	-
Werner Helicase Program Research And Development Service Growth	-	-25.04%	-
The Option	17.23M	17.68M	-
The Option Growth	-	2.58%	-
Polymerase Theta Program Research And Development Service	25.78M	13.75M	-
Polymerase Theta Program Research And Development Service Growth	-	-46.65%	-
Methionine Adenosyl Transferase2 A Program Research And Development	16.14M	9.49M	-
Methionine Adenosyl Transferase2 A Program Research And Development Growth	-	-41.24%	-

Frequently Asked Questions

Growth & Financials

IDEAYA Biosciences, Inc. (IDYA) reported $214.8M in revenue for fiscal year 2024.

IDEAYA Biosciences, Inc. (IDYA) saw revenue decline by 70.1% over the past year.

IDEAYA Biosciences, Inc. (IDYA) reported a net loss of $160.7M for fiscal year 2024.

Dividend & Returns

IDEAYA Biosciences, Inc. (IDYA) has a return on equity (ROE) of -32.7%. Negative ROE indicates the company is unprofitable.

IDEAYA Biosciences, Inc. (IDYA) had negative free cash flow of $105.4M in fiscal year 2024, likely due to heavy capital investments.